Knight Therapeutics Announces Launch of WYNZORA® in Canada

MONTREAL, Aug. 20, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the launch of WYNZORA ® , a uniform white aqueous cream containing 0.05 mg/g of calcipotriol (CAL) and 0.5 mg/g of betamethasone dipropionate (BDP), in Canada. WYNZORA ® is indicated for the topical treatment of psoriasis vulgaris in adults and adolescents aged 12 and older. 1

“The launch of WYNZORA ® in Canada reflects our commitment to continuing to grow our Canadian platform and bring innovative treatment options to patients. WYNZORA ® ‘s unique aqueous cream formulation, enabled by PAD Technology™, offers patients and healthcare providers a clinically proven option that combines efficacy with ease of use, an important consideration for a chronic condition that requires long-term management.” said Samira Sakhia, President and Chief Executive Officer, Knight Therapeutics Inc.

Knight obtained the Canadian rights to WYNZORA ® through its June 2025 acquisition of the assets of Paladin Pharma Inc. (“Paladin”). Paladin had entered into a license agreement with MC2 Therapeutics Ltd. (“MC2”) to commercialize WYNZORA ® in Canada in November 2024. MC2 is a private pharmaceutical company headquartered in Hørsholm, Denmark and in Guildford, United Kingdom. Knight announced Health Canada approval of WYNZORA ® in December 2025.

A welcome email is on its way. If you don't see it, please check your junk folder.

WYNZORA ® is a cream-based fixed dose combination of CAL and BDP for topical treatment of psoriasis vulgaris developed by MC2. WYNZORA ® has a broad mode of action by targeting keratinocyte proliferation and differentiation and inhibiting expression of pro-inflammatory hallmark cytokines such as IL-23, IL-17A/F and TNF-α. In WYNZORA ® , the combination of CAL and BDP has greater anti-inflammatory and anti-proliferative effects than either component alone. WYNZORA ® is uniquely enabled by MC2’s formulation and drug delivery system PAD Technology TM , allowing an effective convenient-to-use aqueous cream formulation. WYNZORA ® Cream was first approved in the United States by the FDA in July 2020, followed by approvals in Europe in 2021, Australia in November 2024, and Canada in December 2025.

WYNZORA ® is a registered trademark of MC2. All other trademarks are the property of their respective owners.

Psoriasis is a chronic, immune-mediated inflammatory disease of the skin. 2 It is often characterized by the presence of erythematous plaques, usually covered with silver, flaking scales. These plaques may be itchy or painful; depending on their extent and location, they may also be physically debilitating or socially isolating. 3,4 An estimated 1 million Canadians and 125 million people worldwide, are affected by psoriasis. 4 Chronic plaque psoriasis (psoriasis vulgaris) is the most common type and accounts for 80% to 90% of cases. 5 The severity of disease may vary among patients, ranging from mild to moderate to severe. 5 The clinical course of psoriasis is unpredictable, with fluctuating severity over time. 6

Common symptoms of psoriasis include itching, redness, flaking and scaling.